VENLO, Netherlands, June 1, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2009 Annual Report on its website at QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2009 has been filed with the U.S. Securities and Exchange Commission on March 17, 2010.  QIAGEN will provide printed copies of the 2009 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2009 Annual Report, please contact PrecisionIR Group, 601 Moorefield Park Drive, Richmond, VA 23236, United States of America, Phone number: +1-888-400-7789, Internet link:


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at

The QIAGEN N.V. logo is available at
CONTACT:  QIAGEN N.V.          IR          +1 301 944 7028          EU: +49 2103 29 11710